{"id":"W3033984526","doi":"10.1136/annrheumdis-2020-eular.1682","title":"FRI0087 DURABILITY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH RHEUMATOID ARTHRITIS OR PSORIASIS OVER THREE YEARS: AN ANALYSIS OF POOLED CLINICAL TRIAL DATA","year":2020,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Pharmaceutical studies and practices","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Sanofi Genzyme; Gilead Sciences; LEO Pharma; Medac; Fresenius Medical Care North America; Celltrion; Astellas Pharma; Eisai; Daiichi-Sankyo; Chugai Pharmaceutical; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Pfizer; Biogen; Celgene; Bristol-Myers Squibb; Samsung; UCB Pharma; Valeant Pharmaceuticals International; Sanofi; Amgen; Galderma; Eli Lilly and Company; GlaxoSmithKline","keywords":"Certolizumab pegol; Medicine; Discontinuation; Internal medicine; Rheumatoid arthritis; Tolerability; Psoriasis; Placebo; Surgery; Adalimumab; Immunology; Adverse effect; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.02886717,0.002014928,0.009286026,0.001584504,0.0004350336,0.002652374,0.001254281,0.001900216,0.002909103],"category_scores_gemma":[0.02442223,0.001026873,0.02366856,0.002212117,0.0008107399,0.001907196,0.001401261,0.002396443,0.0003929995],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008865133,"about_ca_system_score_gemma":0.0008851776,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009068038,"about_ca_topic_score_gemma":0.001682568,"domain_scores_codex":[0.9806522,0.01243576,0.002567545,0.002273538,0.001397588,0.000673318],"domain_scores_gemma":[0.9755993,0.01539894,0.004494517,0.002949024,0.0008823383,0.0006757813],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.4254734,0.0002170905,0.02563407,0.005182783,0.5241417,0.0001606584,0.000100395,0.001580571,0.00134873,0.0001444591,0.0006182727,0.01539788],"study_design_scores_gemma":[0.1271513,0.02630798,0.1273418,0.0007806075,0.7095414,0.0004748651,0.0002019732,0.002779271,0.00121599,0.0007466064,0.003254284,0.0002040413],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7951308,0.190392,0.004296282,0.0004495431,0.0008013873,0.0007414385,0.005725359,0.0001690401,0.002294005],"genre_scores_gemma":[0.9849907,0.008763436,0.001203252,0.0003816332,0.0003062178,0.0004004918,0.003254692,0.00005715031,0.0006423885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02886717,"threshold_uncertainty_score":0.152666,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2336954937084066,"score_gpt":0.4422158753913258,"score_spread":0.2085203816829193,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}